144P First-line cemiplimab monotherapy for advanced non-small cell lung cancer (NSCLC) of squamous histology: Subgroup analysis with 5-year results from EMPOWER-Lung 1
Year: 2024
Type: article
Abstract: Patients with squamous NSCLC have a poorer prognosis than those with non-squamous histology and fewer treatment options. The phase 3 EMPOWER-Lung 1 study (NCT03088540) has demonstrated significant survival benefits of first-line (1L) cemiplimab monotherapy vs chemotherapy and an acceptable safety profile in patients with treatment-naïve squamous or non-squamous NSCLC with PD-L1 expression ≥50% and no EGFR, ALK or ROS1 aberrations. Here, we report 5-year results of patients with squamous NSCLC from this study.
Source: Immuno-Oncology Technology
Authors: T. Makharadze, M. Gogishvili, T. Melkadze, A. Baramidze, A. Sezer, S. Kilickap, M. Gumus, I. Bondarenko, K.D. Penkov, M. Ozguroglu, E. Kalinka, C. Zhu, F. Seebach, E. Kim, H. Magnan, J-F. Pouliot
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,170
OpenAlex ID: W4405375184